Deucravacitinib by Bristol-Myers Squibb can help with psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, and systemic lupus erythematosus.
ulcerative colitis (UC)
Posted inAutoimmune Diseases, New Drugs, Regulatory
Zeposia: New Drug for Ulcerative Colitis
Oral ozanimod will provide clinical remission of ulcerative colitis for a third of patients.
Posted inAutoimmune Diseases, Neuroscience, New Drugs, Regulatory
Zeposia: New Drug to Treat Relapsing Multiple Sclerosis
Bristol-Myers Squibb has come up with ozanimod, a direct competitor to Novartis’ fingolimod and siponimod, for the treatment of multiple sclerosis.